骨髓纤维化患者对莫美替尼治疗贫血反应的预测因素及其对生存的影响
回顾性分析72例未接受过JAK2抑制剂治疗的贫血骨髓纤维化患者,接受莫美替尼中位剂量300mg每日,贫血反应率44%,输血依赖者46%;贫血反应与原发性血小板增多症后骨髓纤维化、较低铁蛋白和较短诊断至治疗时间相关,且与生存改善相关(HR 0.5)。
要点
- 贫血反应率:全部患者44%,血红蛋白<10 g/dl者48%,输血依赖者46%。
- 预测因素:原发性血小板增多症后骨髓纤维化(83% vs 37%,p=.001)、较低铁蛋白(p=.003)、较短诊断至治疗时间(p=.001)。
- 贫血反应者中位生存3.8年 vs 无反应者2.8年(p=.14),多变量分析HR 0.5(p=.02)。
核心结论
- 本研究提示莫美替尼治疗的骨髓纤维化患者中贫血反应与短期生存获益相关。
研究设计与样本
- 回顾性分析72例骨髓纤维化贫血患者,中位年龄68岁,均为JAK2抑制剂初治,接受1/2期莫美替尼临床试验。
- 莫美替尼中位剂量300 mg每日。
主要发现
- 贫血反应率:全部患者44%,血红蛋白<10 g/dl者48%,输血依赖者46%。
- 贫血反应更常见于原发性血小板增多症后骨髓纤维化(83% vs 37%,p=.001)、较低血清铁蛋白(p=.003)和较短诊断至莫美替尼治疗时间(p=.001)。
- 莫美替尼治疗后中位生存3.2年;单变量分析中贫血反应者中位生存3.8年 vs 无反应者2.8年(p=.14)。
- 多变量分析证实贫血反应对生存的有利影响(p=.02;HR 0.5;3/5/10年生存率69%/38%/25%)。
- 输血依赖患者中贫血反应者中位生存3.7年 vs 无反应者1.9年(p=.01;HR 0.3)。
关键数值与推荐
- 贫血反应按正式标准评估。
- Driver突变谱:JAK2 69%,CALR 17%,MPL 8%,三阴性6%;其他突变:ASXL1 39%,SRSF2 17%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We retrospectively reviewed 72 anemic patients with myelofibrosis (MF; median age 68 years), who were JAK2 inhibitor-naïve at the time of study entry to a phase-1/2 momelotinib clinical trial. Driver mutation profile included JAK2 69%, CALR 17%, MPL 8%, and triple-negative 6%; other mutations included ASXL1 39% and SRSF2 17%. Momelotinib was administered at a median dose of 300 mg daily. Anemia response was assessed by formal criteria and documented in 44% of all patients with hemoglobin levels below the sex-adjusted reference range (n = 72), 48% of those with hemoglobin <10 g/dl (n = 54), and 46% of those who were transfusion-dependent at the time of study entry (n = 28). Anemia response was more likely with post-essential thrombocythemia MF (83% vs 37%; p = .001), lower serum ferritin (p = .003), and shorter time from diagnosis to momelotinib therapy (p = .001); the first two variables were also predictive in transfusion-dependent patients. Post-momelotinib median survival was 3.2 years; in univariate analysis, survival was superior in anemia responders (median 3.8 vs. 2.8 years; p = .14) and in the presence of type 1/like CALR mutation and inferior in the presence of age > 65 years, ASXL1/SRSF2 mutation, unfavorable karyotype, DIPSS-plus high risk, red cell transfusion need and higher serum ferritin. Multivariable analysis confirmed the favorable impact of anemia response on survival (p = .02; HR 0.5, 3/5/10-year survival; 69%/38%/25%). This survival advantage was also noted in transfusion-dependent patients (3.7 vs. 1.9 years; p = .01; HR 0.3) and appeared to be restricted to patients with an unfavorable genetic profile. The current study suggests a short-term survival benefit associated with anemia response in momelotinib-treated patients with MF.
引用
- Gangat N, Begna KH, Al-Kali A, et al. Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival. Am J Hematol. 2022. PMID: 36349465. doi:10.1002/ajh.26778
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。